Search Browse Earnings

Spyre Therapeutics, Inc.

Nasdaq:SYRE

Pharmaceutical Preparations·WALTHAM, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$886,000

-62.0% YoY

FY 2025

Adj. EBITDA

-$241.6M

-27264.0% margin

FY 2025

Net Income

-$338.8M

-38238.1% margin

FY 2025

EPS (Diluted)

-$25.02

FY 2023

Stock Price

$40.13

-1.1%

2026-03-06

52W Range

$10.91 – $45.76

P/E Ratio

-1.6x

Market Cap

$3.2B

Cash

$188.9M

FY 2025

Total Debt

—

Net Cash

$188.9M

FY 2025

Enterprise Value

$3.0B

Debt / EBITDA

0.8x

FY 2025

EV / EBITDA

-12.3x

Employees

—

CEO

Turtle Cameron

CFO

Burrows Scott L